<p>佛罗里达州温特帕克 --（Newsfile Corp. -2026 年 4 月 1 日）- Adia Nutrition, Inc.（OTCQB: ADIA），一家再生医学、干细胞疗法和高端健康解决方案的领导者，今天宣布了截至 2025 年 12 月 31 日的 10-K 年报的主要亮点。该文件标志着公司从一个休眠壳体成功转型为高增长再生医疗行业活跃参与者的关键一年。</p>
<p>在 2025 年，Adia Nutrition 实现了约 700,508 美元的总收入，相较于 2024 年的 6,380 美元大幅增长。这一增长主要得益于生物产品（约占 63%）和医疗程序（约占 35%）的销售，通过其 Adia Labs 和 Adia Med 部门实现，减少了对补充剂销售的依赖。毛利润达到 191,670 美元，而公司报告的营业亏损为 366,492 美元，净亏损为 395,464 美元。管理层将收入增长归因于临床服务的推出、生物产品销售的增加以及初步的研发和临床活动。</p>
<p>“我们 2025 年的业绩反映了我们在再生医学领域建立可扩展平台战略的成功执行，” Adia Nutrition 首席执行官 Larry Powalisz 表示。“随着我们将重点转向高潜力的干细胞和生物产品，收入增长超过 100 倍。凭借我们最近获得的完整 SEC 报告状态，我们现在为更大的透明度、投资者信心和加速增长以实现潜在的上市做好了准备。”</p>
<p>10-K 报告和近期发展中的关键业务和运营亮点：</p>
<ul>
<li>再生医学聚焦：通过 Adia Med，公司提供包括干细胞疗法在内的专业治疗，适用于骨科疾病、疼痛管理和伤口修复。Adia Med 还支持自体造血干细胞移植（AHSCT），用于多发性硬化等批准适应症，以及富血小板血浆（PRP）疗法。Adia Labs 采购并销售高端生物产品，如 AdiaVita（脐带血来源的干细胞和外泌体）和 AdiaLink（羊水来源的外泌体），均在严格的 FDA 第 361 条和 AATB 标准下加工。</li>
<li>多元化业务：公司通过 Adia Med（临床服务）、Adia Labs（生物产品销售）和 Biolete（营养补充剂，包括含蘑菇提取物的蛋白咖啡）运营。它还持有相关营养业务的股权。</li>
<li>完整 SEC 报告里程碑：在 2026 年 2 月，Adia 的 10 号表格注册声明生效，使公司成为 1934 年证券交易法下的完全报告实体。这使得公司能够通过 10-K、10-Q 和 8-K 文件进行定期审计披露，符合主要交易所的标准，并支持未来潜在的纳斯达克上市努力。</li>
<li>运营基础设施：公司在佛罗里达州温特帕克维持一家诊所和运营，拥有一支小而专注的团队，并由包括专注于再生疗法的医生在内的医疗专家组成董事会。</li>
<li>市场机会：Adia 正在利用不断扩大的干细胞疗法市场，预计在未来几年将实现显著增长，强调最小操作的、FDA 注册的异体和自体产品。</li>
</ul>
<p>公司指出，2025 年在临床协议、人员、设备和研发方面的持续投资导致了更高的运营费用。管理层预计年度运营成本在 450,000 至 750,000 美元之间，并预计收入势头将持续，同时根据需要探索额外的资本来源。由于历史亏损和对融资的依赖，披露了对持续经营的重大疑虑，这与该行业早期阶段的增长公司一致。</p>
<p>Adia Nutrition 致力于在个性化医疗领域的创新，通过科学支持的再生解决方案弥补传统系统的不足。</p>
<p><strong>如有问题、咨询或需要更多信息，</strong> 请联系 Larry Powalisz，邮箱：ceo@adiamed.com，电话：321-788-0850。</p>
<p><strong>关于 ADIA Nutrition Inc.：</strong></p>
<p>Adia Nutrition Inc.（OTCQB: ADIA）总部位于佛罗里达州温特帕克，是一家通过创新推动医疗保健的上市公司。该公司专注于销售干细胞和再生产品，如 AdiaVita 和 AdiaLink，通过其实验室部门 Adia Labs LLC，正在扩展包括可报销的伤口护理产品。Adia 还在全国范围内发展 Adia Med 诊所，专注于骨科、疼痛管理和伤口修复。Adia Med 诊所还提供专业的再生治疗，如干细胞疗法和富血小板血浆（PRP），先进治疗包括治疗性血浆置换（TPE）和自体造血干细胞移植（aHSCT），以及伤口修复服务。</p>
<p>收入通过服务费用、产品销售、股权投资和医疗治疗的保险报销产生。此外，Adia Nutrition Inc.还投资于相关业务，如 Cement Factory LLC，一家具有共同价值观并专注于健康和保健的营养和补充剂公司。通过与顶级医疗实体的大胆合作以及对标准化、FDA 批准的实验室协议的坚定承诺，Adia Nutrition Inc.正在革新医疗保健，点燃全国范围内的运动，以赋能社区，提供突破性的再生解决方案和充满活力的整体健康。</p>
<p>网站：www.adianutrition.com</p>
<p>网站：www.adiamed.com</p>
<p>网站：www.adialabs.com</p>
<p>网站：www.cementfactory.co</p>
<p>推特（X）：@ADIA_Nutrition</p>
<p><strong>安全港声明：</strong> 本新闻稿包含根据 1933 年证券法第 27A 条和 1934 年证券交易法第 21E 条的定义的前瞻性陈述。这些前瞻性陈述基于管理层当前的计划和预期，并受到一些不确定性和风险的影响，这些因素可能会显著影响公司的当前计划和预期，以及未来的运营结果和财务状况。有关可能影响公司商业前景并导致实际结果与前瞻性陈述中描述的结果存在重大差异的风险和因素的更详细列表，可以在公司向证券交易委员会和 OTC Markets, Inc. OTC 披露和新闻服务提交的报告和其他文件中找到。公司没有义务因新信息、未来事件或其他原因公开更新或修订任何前瞻性陈述。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/10520/290856_0ee6e416f4dc4a12_logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="200" height="30" original-src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/10520/290856_0ee6e416f4dc4a12_logo.jpg"/></p>
<p>要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/290856</p>
<p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/290856/375?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/290856/375"/></p>

2 倍做多纳斯达克生物技术 ETF - ProShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

动态生物技术与基因组 ETF - Invesco

<p>Adia Nutrition, Inc. 在其 2025 年年报中报告了显著的收入增长，达到了约 700,508 美元，较 2024 年的 6,380 美元大幅提升。这一增长归因于生物产品和医疗程序销售的增加。公司已转变为完全按照 SEC 法规报告的实体，增强了透明度并为纳斯达克上市创造了潜力。尽管运营亏损为 366,492 美元，管理层对未来的收入增长势头和在再生医学领域的持续投资仍持乐观态度。Adia Nutrition 专注于创新的医疗解决方案，包括干细胞疗法和生物产品</p>

<p>Winter Park, Florida--(Newsfile Corp. - April 1, 2026) - Adia Nutrition, Inc. (OTCQB: ADIA), a leader in regenerative medicine, stem cell therapies, and premium wellness solutions, today announced key highlights from its Form 10-K annual report for the year ended December 31, 2025. The filing marks a pivotal year of operational expansion following the company's successful transition from a dormant shell to an active player in the high-growth regenerative healthcare sector.</p>
<div class="lb-trans"><p>佛罗里达州温特帕克 --（Newsfile Corp. -2026 年 4 月 1 日）- Adia Nutrition, Inc.（OTCQB: ADIA），一家再生医学、干细胞疗法和高端健康解决方案的领导者，今天宣布了截至 2025 年 12 月 31 日的 10-K 年报的主要亮点。该文件标志着公司从一个休眠壳体成功转型为高增长再生医疗行业活跃参与者的关键一年。</p>
</div><p>In 2025, Adia Nutrition achieved total revenue of approximately $700,508, representing a substantial increase from just $6,380 in 2024. This growth was driven primarily by sales of biologic products (approximately 63%) and medical procedures (approximately 35%) through its Adia Labs and Adia Med divisions, with a reduced reliance on supplement sales. Gross profit reached $191,670, while the company reported an operating loss of $366,492 and a net loss of $395,464. Management attributes the improved top-line performance to the launch of clinical services, increased biologics sales, and initial R&amp;D and clinical activities.</p>
<div class="lb-trans"><p>在 2025 年，Adia Nutrition 实现了约 700,508 美元的总收入，相较于 2024 年的 6,380 美元大幅增长。这一增长主要得益于生物产品（约占 63%）和医疗程序（约占 35%）的销售，通过其 Adia Labs 和 Adia Med 部门实现，减少了对补充剂销售的依赖。毛利润达到 191,670 美元，而公司报告的营业亏损为 366,492 美元，净亏损为 395,464 美元。管理层将收入增长归因于临床服务的推出、生物产品销售的增加以及初步的研发和临床活动。</p>
</div><p>&#34;Our 2025 results reflect the successful execution of our strategy to build a scalable platform in regenerative medicine,&#34; said Larry Powalisz, Chief Executive Officer of Adia Nutrition. &#34;Revenue grew over 100-fold as we shifted focus toward high-potential stem cell and biologic offerings. With our recent achievement of full SEC reporting status, we are now positioned for greater transparency, investor confidence, and accelerated growth toward potential uplisting.&#34;</p>
<div class="lb-trans"><p>“我们 2025 年的业绩反映了我们在再生医学领域建立可扩展平台战略的成功执行，” Adia Nutrition 首席执行官 Larry Powalisz 表示。“随着我们将重点转向高潜力的干细胞和生物产品，收入增长超过 100 倍。凭借我们最近获得的完整 SEC 报告状态，我们现在为更大的透明度、投资者信心和加速增长以实现潜在的上市做好了准备。”</p>
</div><p>Key Business and Operational Highlights from the 10-K and Recent Developments:</p>
<div class="lb-trans"><p>10-K 报告和近期发展中的关键业务和运营亮点：</p>
</div><ul>
<li>Regenerative Medicine Focus: Through Adia Med, the company offers specialized treatments including stem cell therapies for orthopedic conditions, pain management, and wound repair. Adia Med also supports autologous hematopoietic stem cell transplantation (AHSCT) for approved indications such as multiple sclerosis, alongside platelet-rich plasma (PRP) therapies. Adia Labs procures and sells premium biologic products like AdiaVita (umbilical cord blood derived stem cells and exosomes) and AdiaLink (amniotic fluid-derived exosomes), both processed under strict FDA Section 361 and AATB standards.</li>
<li>Diversified Segments: The company operates through Adia Med (clinical services), Adia Labs (biologics sales), and Biolete (nutritional supplements, including protein coffee with mushroom extracts). It also holds an equity stake in aligned nutrition businesses.</li>
<li>Full SEC Reporting Milestone: In February 2026, Adia's Form 10 registration statement became effective, making the company a fully reporting entity under the Securities Exchange Act of 1934. This enables regular audited disclosures via 10-K, 10-Q, and 8-K filings, aligning with standards for major exchanges and supporting potential future NASDAQ uplisting efforts.</li>
<li>Operational Infrastructure: The company maintains a clinic and operations in Winter Park, Florida, with a small but focused team supplemented by medical experts on the board, including physicians specializing in regenerative therapies.</li>
<li>Market Opportunity: Adia is capitalizing on the expanding stem cell therapy market, projected to reach significant growth in the coming years, by emphasizing minimally manipulated, FDA-registered allogeneic and autologous products.</li>
</ul>
<div class="lb-trans"><ul>
<li>再生医学聚焦：通过 Adia Med，公司提供包括干细胞疗法在内的专业治疗，适用于骨科疾病、疼痛管理和伤口修复。Adia Med 还支持自体造血干细胞移植（AHSCT），用于多发性硬化等批准适应症，以及富血小板血浆（PRP）疗法。Adia Labs 采购并销售高端生物产品，如 AdiaVita（脐带血来源的干细胞和外泌体）和 AdiaLink（羊水来源的外泌体），均在严格的 FDA 第 361 条和 AATB 标准下加工。</li>
<li>多元化业务：公司通过 Adia Med（临床服务）、Adia Labs（生物产品销售）和 Biolete（营养补充剂，包括含蘑菇提取物的蛋白咖啡）运营。它还持有相关营养业务的股权。</li>
<li>完整 SEC 报告里程碑：在 2026 年 2 月，Adia 的 10 号表格注册声明生效，使公司成为 1934 年证券交易法下的完全报告实体。这使得公司能够通过 10-K、10-Q 和 8-K 文件进行定期审计披露，符合主要交易所的标准，并支持未来潜在的纳斯达克上市努力。</li>
<li>运营基础设施：公司在佛罗里达州温特帕克维持一家诊所和运营，拥有一支小而专注的团队，并由包括专注于再生疗法的医生在内的医疗专家组成董事会。</li>
<li>市场机会：Adia 正在利用不断扩大的干细胞疗法市场，预计在未来几年将实现显著增长，强调最小操作的、FDA 注册的异体和自体产品。</li>
</ul>
</div><p>The company noted ongoing investments in clinical protocols, staffing, equipment, and R&amp;D, which contributed to higher operating expenses in 2025. Management expects annual operating costs in the range of $450,000-$750,000 and anticipates continued revenue momentum while exploring additional capital sources as needed. Substantial doubt about going concern was disclosed due to historical losses and reliance on financing, consistent with early-stage growth companies in the sector.</p>
<div class="lb-trans"><p>公司指出，2025 年在临床协议、人员、设备和研发方面的持续投资导致了更高的运营费用。管理层预计年度运营成本在 450,000 至 750,000 美元之间，并预计收入势头将持续，同时根据需要探索额外的资本来源。由于历史亏损和对融资的依赖，披露了对持续经营的重大疑虑，这与该行业早期阶段的增长公司一致。</p>
</div><p>Adia Nutrition remains committed to innovation in personalized healthcare, bridging gaps in traditional systems with compassionate, science-backed regenerative solutions.</p>
<div class="lb-trans"><p>Adia Nutrition 致力于在个性化医疗领域的创新，通过科学支持的再生解决方案弥补传统系统的不足。</p>
</div><p><strong>For questions, inquiries, or additional information,</strong> please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850.</p>
<div class="lb-trans"><p><strong>如有问题、咨询或需要更多信息，</strong> 请联系 Larry Powalisz，邮箱：ceo@adiamed.com，电话：321-788-0850。</p>
</div><p><strong>About ADIA Nutrition Inc.:</strong></p>
<div class="lb-trans"><p><strong>关于 ADIA Nutrition Inc.：</strong></p>
</div><p>Adia Nutrition Inc. (OTCQB: ADIA), based in Winter Park, Florida, is a publicly traded company advancing healthcare through innovation. The company specializes in sales of stem cell and regenerative products, such as AdiaVita and AdiaLink, through its lab division, Adia Labs LLC, which is expanding to include insurance-billable wound care products. Adia is also growing nationwide with Adia Med clinics, specializing in orthopedic, pain management, and wound repair. Adia Med clinics also offer specialized regenerative treatments like stem cell therapies and platelet-rich plasma (PRP), advanced treatments including therapeutic plasma exchange (TPE) and autologous hematopoietic stem cell transplantation (aHSCT), and wound repair services.</p>
<div class="lb-trans"><p>Adia Nutrition Inc.（OTCQB: ADIA）总部位于佛罗里达州温特帕克，是一家通过创新推动医疗保健的上市公司。该公司专注于销售干细胞和再生产品，如 AdiaVita 和 AdiaLink，通过其实验室部门 Adia Labs LLC，正在扩展包括可报销的伤口护理产品。Adia 还在全国范围内发展 Adia Med 诊所，专注于骨科、疼痛管理和伤口修复。Adia Med 诊所还提供专业的再生治疗，如干细胞疗法和富血小板血浆（PRP），先进治疗包括治疗性血浆置换（TPE）和自体造血干细胞移植（aHSCT），以及伤口修复服务。</p>
</div><p>Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments. Additionally, Adia Nutrition Inc. invests in aligned businesses such as Cement Factory LLC, a nutrition and supplement company with shared values and a focus on health and wellness. Through bold partnerships with top-tier medical entities and unwavering dedication to standardized, FDA-approved lab protocols, Adia Nutrition Inc. is revolutionizing healthcare, igniting a nationwide movement to empower communities with groundbreaking regenerative solutions and vibrant, holistic wellness.</p>
<div class="lb-trans"><p>收入通过服务费用、产品销售、股权投资和医疗治疗的保险报销产生。此外，Adia Nutrition Inc.还投资于相关业务，如 Cement Factory LLC，一家具有共同价值观并专注于健康和保健的营养和补充剂公司。通过与顶级医疗实体的大胆合作以及对标准化、FDA 批准的实验室协议的坚定承诺，Adia Nutrition Inc.正在革新医疗保健，点燃全国范围内的运动，以赋能社区，提供突破性的再生解决方案和充满活力的整体健康。</p>
</div><p>Website: www.adianutrition.com</p>
<div class="lb-trans"><p>网站：www.adianutrition.com</p>
</div><p>Website: www.adiamed.com</p>
<div class="lb-trans"><p>网站：www.adiamed.com</p>
</div><p>Website: www.adialabs.com</p>
<div class="lb-trans"><p>网站：www.adialabs.com</p>
</div><p>Website: www.cementfactory.co</p>
<div class="lb-trans"><p>网站：www.cementfactory.co</p>
</div><p>Twitter (X): @ADIA_Nutrition</p>
<div class="lb-trans"><p>推特（X）：@ADIA_Nutrition</p>
</div><p><strong>Safe Harbor:</strong> This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.</p>
<div class="lb-trans"><p><strong>安全港声明：</strong> 本新闻稿包含根据 1933 年证券法第 27A 条和 1934 年证券交易法第 21E 条的定义的前瞻性陈述。这些前瞻性陈述基于管理层当前的计划和预期，并受到一些不确定性和风险的影响，这些因素可能会显著影响公司的当前计划和预期，以及未来的运营结果和财务状况。有关可能影响公司商业前景并导致实际结果与前瞻性陈述中描述的结果存在重大差异的风险和因素的更详细列表，可以在公司向证券交易委员会和 OTC Markets, Inc. OTC 披露和新闻服务提交的报告和其他文件中找到。公司没有义务因新信息、未来事件或其他原因公开更新或修订任何前瞻性陈述。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/10520/290856_0ee6e416f4dc4a12_logo.jpg" alt="" original-src="https://images.newsfilecorp.com/files/10520/290856_0ee6e416f4dc4a12_logo.jpg"/></p>
<p>To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290856</p>
<div class="lb-trans"><p>要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/290856</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/290856/375" alt="" original-src="https://api.newsfilecorp.com/newsinfo/290856/375"/></p>

Adia Nutrition, Inc. Reports Strong Revenue Growth in 2025 Annual Report, Highlighting Transition to Regenerative Medicine and Full SEC Reporting Status | ADIA Stock News

StockTitan

医疗业 ETF - SPDR

生物科技 ETF - VanEck Vectors

基因改革 ETF - ARK

ADMA生物制药

纽交所高增长板生物技术指数 ETF - First Trust

Aadi Biosciences

标普生物技术 3 倍做多 - Direxion

标普生物技术 ETF - SPDR

美国制药 ETF - iShares

医疗业 ETF - Vanguard

Invesco Nasdaq Biotechnology ETF

医药突破 ETF - ALPS

Adia Nutrition, Inc. 在 2025 年年度报告中显示出强劲的收入增长，突出其向再生医学的转型以及全面的 SEC 报告状态 | ADIA 股票新闻